Novo Nordisk will pay Lexicon $1 billion up front to license its experimental obesity treatment. The news sent penny stock Lexicon flying.

However, social media paints a very different picture of GLP-1 usage. TikTok, in particular, is flooded with posts promoting rapid, extreme weight loss – sometimes as much as 10 to 15 pounds in ...

According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...

Drugs like Ozempic, Wegovy, and Saxenda have become hugely popular. But could they cause psychological side effects in their ...

“Big picture, the deal aligns with Novo’s strategy to maintain dominance in the obesity space by adding complementary mechanisms to pair with their GLP-1 franchise, and we look forward to more ...

Arguably the most pressing question facing clinicians and patients today is not “which treatment works?” but “which treatment ...

I caught myself being weird about food again. I was trying to get a colleague to eat some sriracha-flavoured edamame beans.

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...

CHICAGO -- Coming this weekend, the American College of Cardiology (ACC) annual conference will feature research exploring ...

A groundbreaking study from the University of British Columbia has revealed a potentially disturbing side effect for those ...